In addition, the results of our study also have translational potential as they introduce the possibility of future use of PARP inhibitors as therapeutic agents or adjuvants in a significant subset of cancers where the activity of TETs is disturbed towards decreased hydroxymethylation. The gene discussed is PARP1; the disease is cancer.